Clinical Trial Update: The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients [NA]

View source ↗

Summary

A clinical trial update describes testing a four-drug combination (daratumumab, cabozantinib, pomalidomide, and dexamethasone) for high-risk first-relapsed or p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Cabometyx (cabozantinib) (cabozantinib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Pomalyst (pomalidomide) (pomalidomide)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Multiple Myeloma, Carfilzomib | NA | Status: NOT_YET_RECRUITING